Recent Updates
Recently added Catalysts

Desvenlafaxine Sustained-Release

Phase 3

Major Depressive Disorder | Small molecule | Psychiatry |Pfizer, Inc.|Last Updated: Jan 15, 2019

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials5
Total Enrollment2,563

FDA Designations

No designations recorded

Clinical trial landscape

Desvenlafaxine Sustained-Release · 5 trials · 1 indication

Phase 3 5
NCT01372150A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDDMajor Depressive Disorder
COMPLETED340 Analytics
NCT01371734A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDDMajor Depressive Disorder
COMPLETED363 Analytics
NCT00887224Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive DisorderMajor Depressive Disorder
COMPLETED874 Analytics
NCT00863798Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive DisorderMajor Depressive Disorder
COMPLETED682 Analytics
NCT00831415Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)Major Depressive Disorder
COMPLETED304 Analytics
PHASE3COMPLETED
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Major Depressive DisorderUnlock trial analytics
PHASE3COMPLETED
A Study Of DVS SR In Treatment Of Children And Adolescent Outpatients With MDD
Major Depressive DisorderUnlock trial analytics
PHASE3COMPLETED
Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder
Major Depressive DisorderUnlock trial analytics
PHASE3COMPLETED
Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder
Major Depressive DisorderUnlock trial analytics
PHASE3COMPLETED
Study Evaluating Long-Term Safety of Desvenlafaxine Succinate Sustained Release With Japanese Adult Subjects in Major Depressive Disorder (MDD)
Major Depressive DisorderUnlock trial analytics

Study Endpoints

Primary Endpoints

Change From Baseline to Week 8 in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score
Baseline and Week 8

Clinician-rated interview-based scale (with both child and parent or guardian) to assess 17 distinct symptom areas to derive an index of depression severity. Discrepancies between informants' responses were resolved by using most impaired rating given by valid informant. Rated on a 7-point scale; range from 1 (no impairment) to 7 (indicates greater impairment). Total score calculated as sum of the 17 items (range 1 to 119); higher score indicates greater impairment. Adjusted mean presented.

Change From Baseline to Week 8 in the Children's Depression Rating Scale, Revised (CDRS-R) Total Score (n=102, 104, 106)
Baseline and Week 8

Clinician-rated interview-based scale (with both child and parent or guardian) to assess 17 distinct symptom areas to derive an index of depression severity. Discrepancies between informants' responses were resolved by using most impaired rating given by valid informant. Rated on a 7-point scale; range from 1 (no impairment) to 7 (indicates greater impairment). Total score calculated as sum of the 17 items (range 1 to 119); higher score indicates greater impairment. Mean change from baseline was adjusted for the baseline total score, age group and gender.

Time to Relapse Following Randomization to the Double-blind (DB) Phase: Estimated Probability (Percent) of Relapse at DB Day 185
Double-blind phase Baseline (Study Day 140) up to DB Day 185 (Study Day 325)

Time to relapse analyzed using log-rank test; defined as Hamilton Psychiatric Scale for Depression-17 item score ≥16 at any time during DB phase, discontinuation for unsatisfactory response or efficacy (need for additional or alternate treatment for depression, investigator decision to remove participant for efficacy reasons, or failure to return if investigator determined related to efficacy), hospitalization for depression, suicide attempt, or suicide. Participants who relapsed after DB day 185 or completed DB therapy without relapse were considered as censored on DB day 185 (study day 325).

Change From Baseline in HAM-D17 Total Score at Final On-therapy (FOT) Evaluation (Week 8 or ET)
Baseline and Week 8 (or ET)

HAM-D17: a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on either a 3 point (0 to 2) or a 5 point scale (0 to 4), with 0=none/absent and 4=most severe, for a maximum total score of 50.

Change From Baseline in Hamilton Psychiatric Scale for Depression-17 Item (HAM-D17) Score
Baseline (Extension Study) up to Day 308 or Final On-Therapy (FOT) Evaluation

HAM-D17 is a standardized, clinician-administered rating scale that assesses 17 items characteristically associated with major depression. Items are scored on either a 3-point (0 to 2) or a 5-point scale (0 to 4) with 0=none/absent and 4=most severe, for a maximum total score of 50. Higher scores indicate greater severity. FOT evaluation is defined as the last "on-therapy" evaluation, regardless of the number of days on therapy. Analysis on Observed cases (non-missing data) and Last observation carried forward (LOCF); LOCF method of imputation for any missing value at any visit.

Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)
Baseline (Extension Study) up to Day 329 or 15 days after last dose of study treatment

Any untoward medical occurrence in a participant who received study treatment was considered an AE without regard to possibility of causal relationship. An AE resulting in any of the following outcomes, or deemed to be significant for any other reason, was considered to be an SAE: death; initial or prolonged inpatient hospitalization; a life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly.

Secondary Endpoints

Change From Baseline to Week 8 in the Clinical Global Impression of Severity (CGI-S) Score
Baseline and Week 8
Percentage of Participants by Clinical Global Impression Improvement (CGI-I) Score at Weeks 1, 2, 3, 4, 6, and 8
Baseline and Weeks 1, 2, 3, 4, 6, and 8
Percentage of Participants With a CGI-I Response Defined as a Score of 'Very Much Improved' or 'Much Improved'
Weeks 1, 2, 3, 4, 6, and 8
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
DVS SREXPERIMENTAL -
FluoxetineOTHERActive control for assay sensitivity
PlaceboEXPERIMENTAL -
Experimental Arm 1 - high doseEXPERIMENTAL -
Experimental Arm 2 - low doseEXPERIMENTAL -
Placebo ArmPLACEBO_COMPARATOR -
Desvenlafaxine succinate sustained release 50 mgEXPERIMENTAL -
Desvenlafaxine succinate sustained release 10 mgEXPERIMENTAL -
1EXPERIMENTALDVS SR

Interventions

NameTypeDescription
desvenlafaxine succinate sustained releaseDRUGSubjects randomized to DVS SR group receive 25, 35 or 50 mg/day based on subject weight at the Baseline visit. DVS SR provided as oral tablets.
fluoxetineDRUGSubjects randomized to the fluoxetine group receive 20 mg/day. Fluoxetine provided as oral capsules
placeboDRUGSubjects randomized to the placebo group receive corresponding placebo tablets and/capsules
Desvenlafaxine Succinate Sustained-ReleaseDRUGSubjects randomized to DVS SR treatment arm will receive 25, 35, or 50 mg/day based on subject weight at the Baseline visit.
Desvenlafaxine succinate sustained release 50 mgDRUG50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm.
Desvenlafaxine succinate sustained release 25 mgDRUG25 mg tablet for taper, once daily for 1 week
Desvenlafaxine Succinate Sustained-Release 10mgDRUG10 mg tablet, once daily dosing for 8 weeks
Desvenlafaxine Succinate Sustained-Release 50 mgDRUG50 mg tablet, once daily dosing for 8 weeks
desvenlafaxine succinate sustained release tabletsDRUG25-mg or 50-mg DVS SR tablets taken orally, once daily, at the same time each day. 100 mg dose will be supplied as 2 tablets of 50-mg tablet.
Unlock Study Design Details

Eligibility Criteria

Age Range7 Years to 17 Years
SexALL
Healthy VolunteersNo
Study Sites43

Inclusion Criteria: * Age \>=7 and \<18 years of age * Primary diagnosis of major depressive disorder (MDD) * CDRS-R score \>40 Exclusion Criteria: * History of suicidal behaviour, or requires precaution against suicide * Not in generally healthy medical condition * History of psychosis or bipola...

Countries:United StatesMexicoChileCanadaColombiaCroatiaEstoniaFinlandFranceLatviaLithuaniaPolandRomaniaSlovakiaSouth AfricaJapan
Unlock Eligibility Criteria

Frequently asked questions about Desvenlafaxine Sustained-Release

What is Desvenlafaxine Sustained Release used for?

Desvenlafaxine Sustained Release is an investigational small molecule being studied for major depressive disorder, vasomotor symptoms, and fibromyalgia. It is developed by Pfizer, Inc. (PFE). The drug is in Phase 2 clinical development and is not approved by the FDA.

What does Desvenlafaxine Sustained Release target?

Desvenlafaxine Sustained Release is a small molecule, but its specific molecular target has not been disclosed in the available information. It is being studied for its effects on depression, vasomotor symptoms, and fibromyalgia, though the mechanism of action is not detailed.

Who makes Desvenlafaxine Sustained Release?

Desvenlafaxine Sustained Release is developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker PFE. The drug is currently in Phase 2 clinical development for major depressive disorder, vasomotor symptoms, and fibromyalgia.

What phase is Desvenlafaxine Sustained Release in?

Desvenlafaxine Sustained Release is in Phase 2 clinical development. It is an investigational drug and has not received FDA approval. The development program includes completed Phase 1, Phase 2, and Phase 3 trials across various indications, but the current stage is Phase 2.

What clinical trials is Desvenlafaxine Sustained Release in?

Desvenlafaxine Sustained Release has completed five clinical trials, including NCT00424892 in fibromyalgia, NCT00863798 in major depressive disorder, NCT01190514 a bioequivalence study, and NCT01371734 in children and adolescents with major depressive disorder. All trials are completed, with no active trials ongoing.

Is Desvenlafaxine Sustained Release the same as desvenlafaxine succinate sustained release?

Desvenlafaxine Sustained Release is also known as desvenlafaxine succinate sustained release, often abbreviated as DVS SR. Clinical trials such as NCT01190514 refer to the drug as desvenlafaxine succinate sustained release, confirming that these names describe the same investigational compound.